Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Shandong Chenghui Shuangda Pharmaceutical

02 1Shanghai Minbiotech

03 1Saiming Pharmaceutical

04 1Guangzhou AANpharm Technology

05 1Sichuan Taienkang Pharmaceutical

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass
1784678-61-0
Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D...
Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished Formulation Technology Transfer. With 24 years' expertise, our 6 GMP workshops ensure 100-ton monthly cGMP-compliant capacity. We hold 21 NMPA-registered APIs, 4 US-DMF filings, 8 CEP applications, and passed US FDA, Korea MFDS, and global client audits. Note: Patent-protected products are for R&D use only per Patent Act, not for commercial sale.
Shandong Chenghui Shuangda Pharmaceutical
1784678-61-0
Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediat...
Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shanghai Minbiotech CB

02

Shanghai Minbiotech

5-Bromo-4-fluoro-1-methyl-1H-indazole

CAS Number : 1784678-61-0

End Use API : Orforglipron Calcium Hydrate

About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological AP...

Shanghai Minbiotech CB
1784678-61-0
Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business inv...
Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical intermediates, APIs, and fine chemicals. Since its establishment, we have built major R&D and production bases across China and a global network spanning Asia, Europe, North and South America, and Africa, delivering sustainable, high-quality solutions through chemical innovation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
CB
1784678-61-0
Guangzhou AANpharm Technology is a science-driven producer of key starting materials, pharmaceutical...
Guangzhou AANpharm Technology is a science-driven producer of key starting materials, pharmaceutical intermediates and specialty chemicals for CDMOs, API manufacturers and biotech innovators in regulated and semi-regulated markets. With 25 years of experience, the organization delivers scalable, customized manufacturing under GMP and ISO-compliant systems, supported by integrated R&D and QA/QC labs, complex multi-step synthesis capabilities, flexible batch sizes and dedicated project teams serving clients across North America, Europe and Asia.
blank

04

PEGS Boston Summit
Not Confirmed
arrow
1784678-61-0
Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienk...
Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and sales of generic APIs and intermediates, focusing on high-value APIs such as Dapoxetine Hydrochloride, Tadalafil, and others to meet diverse market needs. Located in the Yuechi Economic Development Zone, Sichuan Province, the manufacturing site spans 100 acres within a provincial-level chemical industry park. Phase one includes 4 independent production lines and a Class D GMP workshop, equipped with 500L to 5000L multifunctional reactors.
blank

05

PEGS Boston Summit
Not Confirmed
arrow